Edition:
United States

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

3.12USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$3.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,263
52-wk High
$6.42
52-wk Low
$2.75

CTIC.OQ

Chart for CTIC.OQ

About

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)
No analyst recommendations are available for CTIC.OQ.

Overall

Beta: 0.88
Market Cap(Mil.): $141.41
Shares Outstanding(Mil.): 42.98
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 79.56 32.84
EPS (TTM): -1.80 -- --
ROI: -85.83 2.86 14.86
ROE: -127.14 5.27 16.11

BRIEF-CTI Biopharma announces european medicines agency validation of Pacritinib

* CTI Biopharma announces european medicines agency validation of pacritinib marketing authorization application for patients with myelofibrosis who have thrombocytopenia

Jul 13 2017

BRIEF-Stonepine Capital Management LLC reports 7.6 pct passive stake in CTI Biopharma Corp as of June 6, 2017

* Stonepine Capital Management LLC reports 7.6 percent passive stake in cti biopharma corp as of june 6, 2017 - SEC filing Source text - (http://bit.ly/2tycnHF) Further company coverage:

Jun 22 2017

BRIEF-Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp

* Orbimed Advisors Llc reports 11.6 percent passive stake in CTI Biopharma Corp as of June 9 Source text: (http://bit.ly/2sg61MT) Further company coverage:

Jun 15 2017

BRIEF-CTI Biopharma announces pricing of underwritten public offering of $45 mln of convertible preferred stock

* CTI Biopharma prices underwritten public offering of $45 million of convertible preferred stock

Jun 06 2017

BRIEF-CTI Biopharma announces proposed public offering of convertible preferred stock

* CTI Biopharma announces proposed public offering of convertible preferred stock

Jun 05 2017

BRIEF-CTi Biopharma reports Q1 revenue $800,000

* CTi Biopharma Corp - As of March 31, 2017, cash and cash equivalents totaled $33.3 million, compared to $44.0 million as of December 31, 2016 Source text for Eikon: Further company coverage:

May 03 2017

BRIEF-Servier,CTI Biopharma expand Pixuvri license and collaboration agreement

* Servier and CTI Biopharma expand license and collaboration agreement to develop and commercialize Pixuvri

Apr 25 2017

BRIEF-CTI Biopharma announces license and agreement expansion with Servier to commercialize Pixuvri

* Servier and CTI biopharma expand license and collaboration agreement to develop and commercialize Pixuvri

Apr 25 2017

BRIEF-CTI Biopharma Q4 loss per share $0.23

* Cti biopharma reports fourth quarter and full year 2016 financial results

Mar 02 2017

Earnings vs. Estimates